Dasatinib. En ny tyrosinkinaseinhibitor til behandling af kronisk myeloid leukaemi
Engelsk titel: Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia
Läs online
Författare:
Bjerrum O
;
Dufva IH
;
Stentoft J
;
Hasselbach HC
Email: ole.weis.bjerrum@rh.regionh.dk
Språk: Dan
Antal referenser: §0
Dokumenttyp:
Artikel
UI-nummer: 08021258
Sammanfattning
Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understanding the biology of the tyrosin kinase led to targeted therapy, inhibiting the ATP-binding site by a small molecule - imatinib (Glivec). A novel 2nd generation tyrosin kinase inhibitor - dasatinib (Sprycel) - is now available in cases of insufficient response or intolerance to imatinib.